PTC Therapeutics, Inc. (PTCT) is listed on NASDAQ in Pharmaceutical Stocks. It is $70.09, -2.40%, with a $5.8B market cap. RSI is 38.5, near oversold. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 38.5 Near Oversold
Market Cap $5.8B
Volume 498.1K
Fundamentals — 10-Q Q2 2026
Revenue $633.1M
Net Income $80.7M
EPS $0.90
Operating Margin 30.6%
Net Margin 12.7%
Debt / Equity -3.2x
P/E Ratio 77.9x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Schmertzler Michael | Insider | Sell | 25,000 | $72.26 | $1.8M | 2026 Aug 27 |
| Schmertzler Michael | Insider | Sell | 25,000 | $72.22 | $1.8M | 2026 Aug 20 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2,813 | $72.57 | $204,127 | 2026 Aug 17 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 10,292 | $68.57 | $705,722 | 2026 Aug 4 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER | Sell | 3,494 | $80.35 | $280,743 | 2026 Jul 14 |
| Smith Mary L. | Insider | Sell | 15,834 | $90.00 | $1.4M | 2026 Jul 9 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 2,464 | $90.25 | $222,376 | 2026 Jul 9 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 46,774 | $87.52 | $4.1M | 2026 Jul 7 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 5,079 | $85.08 | $432,118 | 2026 Jul 6 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 8,130 | $85.26 | $693,151 | 2026 Jun 26 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 26,283 | $85.78 | $2.3M | 2026 Jun 25 |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | Sell | 23,749 | $80.90 | $1.9M | 2026 Jun 22 |
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | Sell | 19,686 | $75.56 | $1.5M | 2026 Jun 17 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 10,462 | $78.65 | $822,868 | 2026 Jun 17 |
| Pauwels Eric | CHIEF BUSINESS OFFICER | Sell | 21,277 | $75.00 | $1.6M | 2026 Jun 10 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2,812 | $72.18 | $202,958 | 2026 May 15 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 12,572 | $72.95 | $917,154 | 2026 May 14 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 3,540 | $78.97 | $279,570 | 2026 May 8 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER | Sell | 2,850 | $70.91 | $202,094 | 2026 Apr 21 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Sell | 2,265 | $69.45 | $157,293 | 2026 Apr 6 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $144.22 | 47.1 | $9.3B |
| | $248.08 | 44.5 | -- |
Take PTCT further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put PTCT in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when PTC Therapeutics, Inc. next reports.
Set alerts on PTCT
Get notified when PTC Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free